Leerink Partnrs Lifts Earnings Estimates for Gossamer Bio

Gossamer Bio, Inc. (NASDAQ:GOSS) – Equities researchers at Leerink Partnrs raised their FY2024 earnings estimates for Gossamer Bio in a report released on Monday, November 11th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($0.32) for the year, up from their previous forecast of ($0.41). The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share. Leerink Partnrs also issued estimates for Gossamer Bio’s Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($0.95) EPS and FY2026 earnings at ($0.79) EPS.

Gossamer Bio (NASDAQ:GOSS) last announced its earnings results on Thursday, November 7th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.04. The firm had revenue of $9.48 million during the quarter, compared to analysts’ expectations of $4.52 million.

A number of other research analysts also recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Gossamer Bio in a report on Monday, November 11th. Wedbush reiterated an “outperform” rating and set a $4.00 target price on shares of Gossamer Bio in a research note on Tuesday, August 13th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Gossamer Bio has an average rating of “Buy” and a consensus target price of $9.20.

Gossamer Bio Stock Performance

NASDAQ:GOSS opened at $0.74 on Thursday. Gossamer Bio has a 1-year low of $0.50 and a 1-year high of $1.60. The stock has a market cap of $167.71 million, a P/E ratio of -2.31 and a beta of 1.96. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74. The firm has a 50-day moving average of $0.93 and a two-hundred day moving average of $0.86.

Institutional Trading of Gossamer Bio

Hedge funds and other institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new position in shares of Gossamer Bio in the 1st quarter worth approximately $34,000. Vanguard Group Inc. boosted its holdings in Gossamer Bio by 1.1% in the first quarter. Vanguard Group Inc. now owns 11,763,784 shares of the company’s stock worth $13,881,000 after purchasing an additional 128,150 shares during the period. Acadian Asset Management LLC increased its stake in Gossamer Bio by 51.6% during the first quarter. Acadian Asset Management LLC now owns 2,736,385 shares of the company’s stock valued at $3,227,000 after purchasing an additional 931,248 shares during the last quarter. Sequoia Financial Advisors LLC raised its holdings in shares of Gossamer Bio by 27.2% during the second quarter. Sequoia Financial Advisors LLC now owns 93,500 shares of the company’s stock worth $84,000 after purchasing an additional 20,000 shares during the period. Finally, Financial Advocates Investment Management raised its holdings in shares of Gossamer Bio by 57.5% during the second quarter. Financial Advocates Investment Management now owns 106,850 shares of the company’s stock worth $96,000 after purchasing an additional 39,000 shares during the period. 81.23% of the stock is owned by institutional investors.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.